SEL-212 low-dose

DRUG2 trials

Sponsors

Swedish Orphan Biovitrum

Conditions

Chronic Gout

Phase 3

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy

CompletedNCT04513366

Swedish Orphan BiovitrumChronic Gout

Start: 2020-08-18End: 2022-12-01Updated: 2025-09-11

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II

CompletedNCT04596540

Swedish Orphan BiovitrumChronic Gout

Start: 2020-11-30End: 2023-01-12Updated: 2025-12-03

Related Papers

Novel 2-drug combo improves treatment possibilities for patients with refractory gout

2023-07-30

Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)

Rheumatology and Therapy2023-04-1721 citations